Auna Announces 3Q26 Financial Results
Auna reports 10% FX-Neutral Revenue Growth and Continued Strong Cash Generation in 3Q2026; Mexico Returns to
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
![]()
Auna (NYSE: AUNA) (“Auna” or the “Company”), a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, announced today unaudited financial results for the third quarter ended September 30, 2026 (“Third quarter 2026” or “3Q26”). Financial results are expressed in Peruvian Soles (“S/” or “PEN” or “Soles”) and are presented in accordance with International Financial Reporting Standards (“IFRS”), unless otherwise noted.
3Q’26 Consolidated Highlights
- Revenue increased 10% YoY FXN and 19% YoY as reported to S/1,325 million, with sequential growth of 3% FXN and 7% as reported
- Adjusted EBITDA was S/231 million, decreasing 4.6% FXN while remaining flat as reported. Sequentially, Adjusted EBITDA was stable FXN and increased 2% as reported
- Mexico Segment Adjusted EBITDA increased 5% YoY in local currency, marking its first year-over-year growth in 2026
- Adjusted EBITDA Margin of 17.5%, compared to 18.4% in 2Q26
- Year to date Net Cash from Operating Activities increased 62% YoY to S/713 million, while Free Cash Flow increased 95% to S/626 million
- Leverage Ratio improved to 3.5x
- Oncology MLR remained stable at 50.7%
- Number of surgeries increased 12% YoY to 23,932
- Number of days hospitalized increased 6% YoY to 144,041
- Number of chemotherapy and radiotherapy sessions increased 7% YoY
Message from Auna’s Executive Chairman and President
The third quarter of 2026 reflected continued strong commercial momentum across our markets, with revenue increasing 10% on an FX-neutral basis. Adjusted EBITDA declined 5% FX-neutral, primarily reflecting profitability pressures in Colombia and Peru, partially offset by improving performance in Mexico. The quarter marked an important milestone in Mexico’s operational recovery, with Segment Adjusted EBITDA returning to year-over-year growth, while continued strong cash generation supported further deleveraging.
In Peru, our resilient integrated model produced revenue growth of 6% year-over-year. The Peru Healthcare network benefited from strong surgical volumes, up 21%, alongside a greater focus on high-complexity procedures. At Oncosalud, we prioritized and grew higher-retention B2B accounts, including two new agreements to onboard 4,000 members. Adjusted EBITDA was impacted by penalties arising from the reconciliation of prior years’ receivables, as well as higher pharmacy and clinical payroll costs associated with increased patient volumes.
In Mexico, we are seeing tangible results from the commercial and operational initiatives implemented earlier this year. Segment Adjusted EBITDA increased 5% year-over-year in local currency, marking its first quarter of year-over-year growth in 2026. This improvement was driven by strong performance in the Monterrey Healthcare network, supported by higher surgical and oncology volumes and improved capacity utilization, which more than offset softer results at Auna Seguros following changes in VAT deductibility. With double-digit oncology revenue growth and improving operating efficiency, we remain focused on further improving this recovery and translating higher utilization into stronger profitability.
In Colombia, revenue increased 12% in local currency, supported by increased hospital capacity in Montería and continued growth in our PGP arrangements. However, Segment Adjusted EBITDA declined 30% in local currency, primarily reflecting two items: first, extraordinary adverse medical-costs under a specific oncology risk-sharing contract, where utilization and treatment costs significantly exceeded contractual assumptions; and second, regulatory price caps on certain high-cost oncology medications. These were further compounded by higher personnel costs across the segment. We have terminated the risk sharing contract to limit further exposure as it represented approximately 4% of Colombia’s revenues and have engaged legal counsel to review all recovery options under the contract. We remain focused on strengthening contract economics, improving operating efficiency, and restoring profitability.
Consolidated cash flow generation remained a significant strength of our platform. Year-to-date Net Cash from Operating activities increased 62% year-over-year to S/713 million, while Free Cash Flow increased 95% to S/626 million, supported by disciplined working capital management, and lower tax payments. This performance contributed to a reduction in net debt and an improvement in our leverage ratio towards 3.5x, bringing it closer to our medium-term target of below 3.0x.
We reached an important milestone with the commencement of construction of Centro Ambulatorio Trecca in Lima. This capital-light public-private partnership will significantly expand our addressable market and provide long-term contractual revenue visibility, reinforcing our strategy of developing capital-efficient growth opportunities.
Looking ahead, as discussed at our recent 2026 Investor Day, we remain confident in the underlying growth trajectory of our business. We reaffirm our full-year 2026 revenue guidance, expecting FX-neutral growth within our 10% to 14% range. However, reflecting the profitability pressures discussed above, particularly in Colombia, we now expect full-year Adjusted EBITDA to remain broadly stable or slightly down year-over-year. Capital expenditures guidance remains unchanged at approximately 4% of revenues.
We remain focused on accelerating growth in Mexico, restoring profitability in Colombia, improving earnings quality and operating efficiency in Peru, and translating our commercial momentum into even stronger cash generation and growing, sustainable returns for our shareholders. We are committed to disciplined execution, strengthening our financial performance, and creating long-term shareholder value.
Overview of 3Q26 Consolidated Results
Revenues increased 10% YoY FXN and 19% as reported to S/1,325 million, with growth measured in local currency (“LC”) across all three markets: 16% in Mexico, 6% in Peru, and 12% in Colombia. In Mexico, growth was driven by higher surgery and oncology volumes at the Monterrey Healthcare network, partially offset by softer performance in Auna Seguros. In Peru, revenue growth was supported by increased healthcare activity, particularly high-complexity procedures and continued growth in Oncosalud’s B2B business. In Colombia, revenue growth benefited from expanded hospital capacity.
Adjusted EBITDA decreased 5% YoY FXN and remained flat as reported at S/231 million, with an Adjusted EBITDA margin of 17.5%. In LC, Segment Adjusted EBITDA increased 5% in Mexico, while declining 6% in Peru and 30% in Colombia. Mexico recorded its first quarter of year-over-year Segment Adjusted EBITDA growth in 2026, driven by improving profitability in the Monterrey Healthcare network, partially offset by softer results at Auna Seguros. In Peru, profitability was impacted by penalties related to the reconciliation of prior years’ receivables, as well as higher MLR from a larger mix of healthcare plans and the ramp up of new B2B oncology plans. In Colombia, profitability was primarily affected by adverse medical-costs under a specific oncology risk-sharing contract, which Auna has since terminated and regulatory price caps on certain high-cost oncology medications.
Reported results were impacted by foreign exchange fluctuations, including a 3% appreciation of the Mexican Peso (MXN) and a 20% appreciation of the Colombian Peso (COP) both against the Peruvian Sol (PEN).
Net finance costs were S/112 million in 3Q26, compared to S/72 million in 3Q25. The increase primarily reflected a S/40 million non-cash FX gain recognized in 3Q25 that did not recur in 3Q26, due to Auna resetting its USD/PEN call spread to 3.40-3.80 in Q425. The remainder of the change was due to an increase in Finance costs consisting of (i) a S/6 million non-cash finance expense related to the future purchase obligation for IMAT Oncomedica in 3Q26 versus S/1 million in 3Q25; and (ii) Interest expense and other costs of S/114 in 3Q26 versus S/115 in 3Q25, and partially offset by Finance income of S/7 million in 3Q26 versus S/4 million in 3Q25. Excluding non-cash effects, Net finance costs were S/107 million in 3Q26, compared to S/110 million in 3Q25.
Net Income was S/24 million in 3Q26, compared to S/53 million in 3Q25 primarily reflecting the absence of the significant S/40 million non-cash FX gain recorded in the prior-year period, partially offset by S/20 million in lower income tax expenses. On a per-share basis, Net Income was S/0.27, based on a weighted average of 74,235,734 basic and diluted shares.
Adjusted Net Income was S/35 million in 3Q26, compared to S/58 million in 3Q25, primarily reflecting the non-cash FX effects described above, partially offset by lower income tax expenses. On a per-share basis, Adjusted Net Income was S/0.41, based on a weighted average of 74,235,734 basic and diluted shares.
For a full version of AUNA’s Third Quarter 2026 Earnings Release, please visit:
https://aunainvestors.com/English/financial-information/quarterly-results/
Conference Call Details
When: 8:00 a.m. Eastern time, November 18, 2026
Who: Mr. Suso Zamora, Executive Chairman of the Board and President; Mrs. Gisele Remy, Chief Financial Officer and Executive Vice President; Mr. Lorenzo Massart, Executive Vice President of Strategy and Equity Capital Markets.
Dial-in: +1 833-461-5787 (U.S. domestic), +1 585-542-9983 (International)
Passcode: 489 711 788
To access Auna′s financial results call via telephone, callers need to press # to be connected to an operator.
Webcast: click here
About AUNA
Auna is a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, prioritizing prevention and concentrating on high-complexity diseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish-Speaking Americas. Founded in 1989, Auna has built one of Latin America′s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of September 30, 2026, Auna’s network included 31 healthcare network facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,361 beds, and 1.4 million healthcare plans.
For more information visit www.aunainvestors.com.
Safe Harbor Statement
This press release contains forward-looking statements. Forward-looking statements convey our current expectations or forecasts of future events. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to differ materially from the forward-looking statements that we make. Forward-looking statements typically are identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “project,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. Forward-looking statements that appear in a number of places in this press release include, but are not limited to, statements regarding the intent, belief or current expectations, regarding various matters, including, our target Leverage Ratio, the results of the key initiatives we are implementing in Mexico, Colombia and Peru, the execution of our strategic plan, including the recovery of our growth levels, our planned investments, our revenue, Adjusted EBITDA and capital expenditure guidance, our expectation for revenue and Adjusted EBITDA growth, the timeline for the construction and commencement of operations at the Centro Ambulatorio Trecca in Lima and our ability to recover any loss under the oncology risk-sharing contract in Colombia. Any or all of our forward-looking statements in this press release may turn out to be inaccurate. Our actual results could differ materially from those contained in forward-looking statements due to a number of factors.
The forward-looking statements in this press release represent our expectations and forecasts as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. For a discussion of the risks facing the Company which could affect whether these forward-looking statements are realized, see our Form 20-F filing with the U.S. Securities and Exchange Commission (the “SEC”).
Financial Guidance Disclaimer
Auna′s guidance is based on management’s current performance outlook and expected macroeconomic and regulatory conditions in the three countries where the Company operates. Any changes in these conditions could have an impact on the guidance provided.
Auna’s financial guidance reflects management’s current assumptions regarding numerous evolving factors that are difficult to accurately predict, including those discussed in the Risk Factors set forth in the Company’s Form 20-F filed with the SEC. Reconciliations of forward-looking non-IFRS measures, specifically the Leverage Ratio target and Adjusted EBITDA guidance, to the relevant forward-looking IFRS measures are not being provided, as the Company does not currently have sufficient data to accurately estimate the variables and individual adjustments for such guidance and reconciliations. Due to this uncertainty, the Company cannot reconcile projected Adjusted EBITDA to projected net income without unreasonable effort. The financial guidance constitutes forward-looking statements. For more information, see the “Safe Harbor Statement” section in this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261117170113/en/
Media gallery

